329 related articles for article (PubMed ID: 18088233)
1. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.
Nikiforova MN; Nikiforov YE
Expert Rev Mol Diagn; 2008 Jan; 8(1):83-95. PubMed ID: 18088233
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
3. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
4. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
6. [BRAF gene mutation in thyroid cancer].
Kopczyńska E; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
[TBL] [Abstract][Full Text] [Related]
7. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
8. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
9. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
Hamatani K; Eguchi H; Ito R; Mukai M; Takahashi K; Taga M; Imai K; Cologne J; Soda M; Arihiro K; Fujihara M; Abe K; Hayashi T; Nakashima M; Sekine I; Yasui W; Hayashi Y; Nakachi K
Cancer Res; 2008 Sep; 68(17):7176-82. PubMed ID: 18757433
[TBL] [Abstract][Full Text] [Related]
10. [Genetic causes of the thyroid carcinomas].
Jindrichová S; Vlcek P; Bendlová B
Cas Lek Cesk; 2004; 143(10):664-8. PubMed ID: 15584614
[TBL] [Abstract][Full Text] [Related]
11. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.
Salvatore G; Chiappetta G; Nikiforov YE; Decaussin-Petrucci M; Fusco A; Carney JA; Santoro M
Eur J Cancer; 2005 Mar; 41(5):816-21. PubMed ID: 15763659
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
13. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M
Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488
[TBL] [Abstract][Full Text] [Related]
14. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
Ciampi R; Nikiforov YE
Endocrinology; 2007 Mar; 148(3):936-41. PubMed ID: 16946010
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutations in papillary thyroid carcinoma.
Wojciechowska K; Lewinski A
Endocr Regul; 2006 Dec; 40(4):129-38. PubMed ID: 17201587
[TBL] [Abstract][Full Text] [Related]
16. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.
Goutas N; Vlachodimitropoulos D; Bouka M; Lazaris AC; Nasioulas G; Gazouli M
Anticancer Res; 2008; 28(1A):305-8. PubMed ID: 18383861
[TBL] [Abstract][Full Text] [Related]
17. Pathology and genetics of thyroid carcinoma.
DeLellis RA
J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
[TBL] [Abstract][Full Text] [Related]
19. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
Di Cristofaro J; Marcy M; Vasko V; Sebag F; Fakhry N; Wynford-Thomas D; De Micco C
Hum Pathol; 2006 Jul; 37(7):824-30. PubMed ID: 16784981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
